Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride plus trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel plus trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer

被引：0
|
作者：
Pernas Simon, S. [1 ]
Rezai, M. [2 ]
Hauschild, M. [3 ]
Machiels, J. P. [4 ]
Paepke, S. [5 ]
Llombart Cussac, A. [6 ]
机构：
[1] Inst Catala Oncol, Dept Oncol, Barcelona, Spain
[2] Luis Hosp, Dept Obstet & Gynaecol, European Breast Ctr, Dusseldorf Med Ctr, Dusseldorf, Germany
[3] Frauenklin, Dept Obstet & Gynaecol, Rheinfelden, Switzerland
[4] Clin Univ St Luc, Dept Oncol, Brussels, Belgium
[5] Sankt Gertrauden Krankenhaus, Dept Breast Surg, Berlin, Germany
[6] IDIBELL, Inst Catala Oncol, Dept Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.72
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
293P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Prospective Open-Label Randomized Phase II Neoadjuvant Study of Non-Pegylated Liposomal Doxorubicin (MYOCET®) Plus Cyclophosphamide and Trastuzumab Versus Conventional Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in HER2-Positive Breast Cancer Patients.
    Llombart-Cussac, A.
    Pernas-Simon, S.
    Rezai, M.
    Hauschild, M.
    Venturini, M.
    Machiels, J-P
    Paepke, S.
    Luporsi, E.
    Kasiborski, F.
    Kayitalire, L.
    [J]. CANCER RESEARCH, 2011, 71
  • [2] Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
    Rocca, Andrea
    Cortesi, Pietro
    Cortesi, Laura
    Gianni, Lorenzo
    Matteucci, Federica
    Fantini, Lorenzo
    Maestri, Antonio
    Giunchi, Donata Casadei
    Cavanna, Luigi
    Ciani, Rosa
    Falcini, Fabio
    Bagni, Antonella
    Meldoli, Elena
    Dall'Agata, Monia
    Volpi, Roberta
    Andreis, Daniele
    Nanni, Oriana
    Curcio, Annalisa
    Lucchi, Leonardo
    Amadori, Dino
    Fedeli, Anna
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [3] Liposome-encapsulated doxorubicin plus cyclophosphamide followed by trastuzumab plus docetaxel as neoadjuvant therapy for HER2-positive breast cancer (BC): A multicenter single-arm phase II study
    Saracchini, Silvana
    Foltran, Luisa
    Sulfaro, Sandro
    Tuccia, Fausto
    Del Conte, Alessandro
    Bertolla, Manuella
    Bassini, Anna
    Micheli, Elvia
    Manente, Stefania
    Gusso, Giuseppina
    Baresic, Tania
    Tumoio, Salvatore
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide plus /- Trastuzumab Followed by Docetaxel in Locally Advanced Breast Cancer (LABC)
    Tuxen, M. K.
    Cold, S.
    Tange, U. B.
    Soendergaard, S. B.
    Nielsen, D. L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S173 - S173
  • [5] Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
    Wang, Haoqi
    Li, Yuntao
    Qi, Yixin
    Zhao, Erbao
    Kong, Xiangshun
    Yang, Chao
    Yang, Qiqi
    Zhang, Chengyuan
    Liu, Yueping
    Song, Zhenchuan
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer
    Theodoulou, Maria
    Batist, Gerald
    Campos, Susana
    Winer, Eric
    Welles, Lauri
    Hudis, Clifford
    [J]. CLINICAL BREAST CANCER, 2009, 9 (02) : 101 - 107
  • [7] Pegylated liposomal doxorubicin (PLD) combined with docetaxel and trastuzumab in neoadjuvant treatment for HER2-positive breast cancer: A multicenter, randomized, phase II, open-label
    Song, Z.
    Wang, H.
    Yang, Q.
    Li, Y.
    Qi, Y.
    Zhao, E.
    Kong, X.
    Yang, C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S437 - S437
  • [8] Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
    Tian, Chunyu
    Wang, Minghui
    Liu, Hancheng
    Liu, Jianping
    Xu, Mengze
    Ma, Lihui
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (03) : 1041 - 1049
  • [9] Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
    Chunyu Tian
    Minghui Wang
    Hancheng Liu
    Jianping Liu
    Mengze Xu
    Lihui Ma
    [J]. Irish Journal of Medical Science (1971 -), 2023, 192 (3): : 1041 - 1049
  • [10] Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer
    Tuxen, Malgorzata K.
    Cold, Soeren
    Tange, Ulla B.
    Balslev, Eva
    Nielsen, Dorte L.
    [J]. ACTA ONCOLOGICA, 2014, 53 (10) : 1440 - 1445
12345